“3 Years of Tralokinumab Treatment Provides Long-Term Disease Control As Demonstrated by Clinically Meaningful Outcomes in Moderate-to-Severe Atopic Dermatitis”. SKIN The Journal of Cutaneous Medicine 6, no. 6 (November 16, 2022): s78. Accessed March 9, 2026. https://skin.dermsquared.com/skin/article/view/1836.